![Western Blot: Aurora A [p Thr288] Antibody [NBP3-05434] - Western blot analysis of extracts of HeLa and HT-29 cells, using Aurora A antibody (NBP3-05434) at 1:1000 dilution. HeLa cells were treated by Hydroxyurea (4mM) for 20 hours. Hela cells were treated by Nocodazole (50ng/mL) for 20 hours.HT-29 cells were treated by Hydroxyurea (4 mM) for 20 hours or treated by Nocodazole (100ng/mL) for 16 hours. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% BSA. Detection: ECL Basic Kit. Exposure time: 90s.](http://images.novusbio.com/fullsize/Aurora-A-[p-Thr288]-Antibody-Western-Blot-NBP3-05434-img0001.jpg "Western Blot: Aurora A [p Thr288] Antibody [NBP3-05434] - Western blot analysis of extracts of HeLa and HT-29 cells, using Aurora A antibody (NBP3-05434) at 1:1000 dilution. HeLa cells were treated by Hydroxyurea (4mM) for 20 hours. Hela cells were treated by Nocodazole (50ng/mL) for 20 hours.HT-29 cells were treated by Hydroxyurea (4 mM) for 20 hours or treated by Nocodazole (100ng/mL) for 16 hours. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% BSA. Detection: ECL Basic Kit. Exposure time: 90s.")
| Reactivity | HuSpecies Glossary |
| Applications | WB, Simple Western, ELISA |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Format | BSA Free |
| Immunogen | A synthetic phosphorylated peptide around T288 of human Aurora A (NP_003591.2). RTTLC |
| Modification | p Thr288 |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | AURKA |
| Purity | Affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
|
| Application Notes | See Simple Western Antibody Database for Simple Western validation: Tested in CHLA-10, CHLA-258, CHLA-32, CHLA-9, COG-E-352, RD-ES, SK-ES-1, TC-32, TC-71, separated by Size |
|
| Theoretical MW | 46 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
|
| Publications |
|
| Storage | Store at -20C. Avoid freeze-thaw cycles. |
| Buffer | PBS (pH 7.3), 50% glycerol |
| Preservative | 0.02% Sodium Azide |
| Purity | Affinity purified |
![Immunohistochemistry EN-RAGE/S100A12 Antibody [Unconjugated]](https://images.novusbio.com/images2/EN-RAGE_AF1052_Immunohistochemistry_6671.jpg)
![Western Blot EN-RAGE/S100A12 Antibody [Unconjugated]](https://images.novusbio.com/images2/ENRAGE_AF1052_Western_Blot_19098.jpg)
![Simple Western EN-RAGE/S100A12 Antibody [Unconjugated]](https://images.novusbio.com/images2/af1052_human-en-rage-affinity-purified-polyclonal-ab-simple-western-2672021152820.jpg)
| Publication using NBP3-05434 | Applications | Species |
|---|---|---|
| Turaga SM, Vishwakarma V, Hembruff SL et al. Inducing Mitotic Catastrophe as a Therapeutic Approach to Improve Outcomes in Ewing Sarcoma Cancers 2023-10-10 [PMID: 37894278] (Simple Western, Human) | Simple Western | Human |
Secondary Antibodies |
Isotype Controls |
Research Areas for Aurora A Antibody (NBP3-05434)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
| Gene Symbol | AURKA |
![Simple Western: Aurora A [p Thr288] Antibody - BSA Free [NBP3-05434] - Analysis of protein expression post-drug treatment. (A) CHLA-10 and (B) TC-71 cells treated with drugs were assessed for changes in protein expression 24 h post-treatment via capillary electrophoresis-based Wes analysis. Increased protein levels of KIF11, p-KIF11Thr926 AURKA, and p-AURKAThr288 were observed for the drug combination group, whereas KIF15 levels were noticeably lower. Similarly, enhanced cleaved-PARP expression was observed with the combination treatment. The uncropped blots are shown in Figures S8 and S9. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/37894278 ), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp3-05434_rabbit-polyclonal-aurora-a-p-thr288-antibody-308202410445511.jpg "Simple Western: Aurora A [p Thr288] Antibody - BSA Free [NBP3-05434] - Analysis of protein expression post-drug treatment. (A) CHLA-10 and (B) TC-71 cells treated with drugs were assessed for changes in protein expression 24 h post-treatment via capillary electrophoresis-based Wes analysis. Increased protein levels of KIF11, p-KIF11Thr926 AURKA, and p-AURKAThr288 were observed for the drug combination group, whereas KIF15 levels were noticeably lower. Similarly, enhanced cleaved-PARP expression was observed with the combination treatment. The uncropped blots are shown in Figures S8 and S9. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/37894278 ), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![SDS-PAGE TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNF-alpha_210-TA_256.jpg)
![Bioactivity TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNFalpha_210TA_1658.jpg)
![SEC-MALS TNF-alpha [Unconjugated]](https://images.novusbio.com/images/210-ta_recombinant-human-tnf-alpha-protein-sec-mals-35202312244..jpg)
![Immunocytochemistry Notch-4 Antibody [Unconjugated]](https://images.novusbio.com/images/antibody/af3847_human-notch-4-intracellular-domain-affinity-purified-pab-immunocytochemistry-3092021102949.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")